Stock BNTX BIONTECH SE
Add to a list
To use this feature you must be a member
Log inSign up

Company BioNTech SE

Equities

BNTX

US09075V1026

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 01:30:00 27/04/2024 am IST 		5-day change 1st Jan Change
87.21 USD +0.58% Intraday chart for BioNTech SE +0.46% -17.37%
25/04 Sector Update: Health Care Stocks Drop in Afternoon Trading MT
25/04 GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines MT

Business Summary

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Number of employees: 6,133

Sales per Business

USD in Million2022Weight2023Weight Delta
Immunotherapy Technologies
100.0 %
18,193 100.0 % 4,129 100.0 % -77.31%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
78.8 %
13,358 73.4 % 3,255 78.8 % -75.63%
Germany
12.6 %
3,186 17.5 % 522 12.6 % -83.62%
International
8.8 %
1,488 8.2 % 362 8.8 % -75.70%
Turkey
-0.2 %
162 0.9 % -10 -0.2 % -106.09%

Managers

Managers TitleAgeSince
Ugur Sahin CEO
 Chief Executive Officer 58 02/08/02
Özlem Türeci FOU
 Founder 57 02/08/02
Jens Holstein DFI
 Director of Finance/CFO 60 01/21/01
Sierk Poetting COO
 Chief Operating Officer 51 01/14/01
Sean Marett COO
 Chief Operating Officer 59 -
Michael Horowicz IRC
 Investor Relations Contact - -
James Ryan LAW
 General Counsel - 01/18/01
Ryan Richardson PRN
 Corporate Officer/Principal 57 01/18/01

Members of the board

Members of the board TitleAgeSince
Rudolf Staudigl BRD
 Director/Board Member 69 01/22/01
Michael Motschmann BRD
 Director/Board Member 67 02/08/02
Helmut Jeggle CHM
 Chairman 53 02/08/02
Ulrich Wandschneider BRD
 Director/Board Member 63 01/18/01
Baroness Nicola Blackwood BRD
 Director/Board Member - 25/23/25
Anja Morawietz BRD
 Director/Board Member 47 01/22/01

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 248,552,200 214,949,219 ( 86.48 %) 10,826,465 ( 4.356 %) 86.48 %

Shareholders

NameEquities%Valuation
Baillie Gifford & Co.
3.655 %
8,689,182 3.655 % 802 M $
PRIMECAP Management Co.
2.004 %
4,763,453 2.004 % 439 M $
Temasek Holdings Pte Ltd.
1.901 %
4,518,080 1.901 % 417 M $
Harding Loevner LP
1.659 %
3,944,474 1.659 % 364 M $
Flossbach von Storch AG
1.493 %
3,548,660 1.493 % 327 M $
Aperio Group LLC
0.5886 %
1,399,134 0.5886 % 129 M $
UBS AG (Investment Management)
0.4187 %
995,253 0.4187 % 92 M $
Capital Research & Management Co. (World Investors)
0.3949 %
938,747 0.3949 % 87 M $
Altrinsic Global Advisors LLC
0.3173 %
754,388 0.3173 % 70 M $
Quinn Opportunity Partners LLC
0.2838 %
674,583 0.2838 % 62 M $
NameEquities%Valuation
ATS Beteiligungsverwaltung GmbH
43.08 %
104,049,145 43.08 % 9 599 M $
Ugur Sahin
17.10 %
41,295,728 17.10 % 3 810 M $
Helmut Jeggle
0.6318 %
1,525,967 0.6318 % 141 M $
Özlem Türeci
0.3781 %
913,247 0.3781 % 84 M $
Sean Marett
0.3376 %
815,263 0.3376 % 75 M $
Sierk Poetting
0.3063 %
739,784 0.3063 % 68 M $
Sector Gamma AS
0.006203 %
14,982 0.006203 % 1 M $
Ryan Richardson
0.006084 %
14,695 0.006084 % 1 M $
Jens Holstein
0.000671 %
1,620 0.000671 % 149 445 $
Ulrich Wandschneider
0.000613 %
1,480 0.000613 % 136 530 $

Holdings

NameEquities%Valuation
AUTOLUS THERAPEUTICS PLC
20.06%
 33,333,333 20.06% 212,666,665 $
RYVU THERAPEUTICS S.A.
8.29%
 1,917,437 8.29% 26,541,911 $

Company contact information

BioNTech SE

An der Goldgrube 12

55131, Mainz

+49 6131 9084 0

http://www.biontech.de
address BioNTech SE(BNTX)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per region

Ratings for BioNTech SE

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
81.69 EUR
Average target price
106.6 EUR
Spread / Average Target
+30.48%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
LEGEND BIOTECH CORPORATION Stock Legend Biotech Corporation
-24.71% 8.24B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. BNTX Stock
  4. Company BioNTech SE